CRISPitope: A generic platform to model target antigens for adoptive T cell transfer therapy in mouse tumor models
This protocol details the procedure for CRISPR-assisted insertion of epitopes (CRISPitope), a flexible approach for generating tumor cells expressing model CD8+ T cell epitopes fused to endogenously encoded gene products of choice. CRISPitope-engineered tumor cells can be recognized by T cell recept...
Uloženo v:
| Vydáno v: | STAR protocols Ročník 3; číslo 1; s. 101038 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
18.03.2022
Elsevier |
| Témata: | |
| ISSN: | 2666-1667, 2666-1667 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | This protocol details the procedure for CRISPR-assisted insertion of epitopes (CRISPitope), a flexible approach for generating tumor cells expressing model CD8+ T cell epitopes fused to endogenously encoded gene products of choice. CRISPitope-engineered tumor cells can be recognized by T cell receptor-transgenic (TCRtg) CD8+ T cells that are widely used in immunology research. Using mice inoculated with CRISPitope-engineered tumor cells, researchers can investigate how the choice of the target antigen for T cell immunotherapies influences treatment efficacy and resistance mechanisms.
For complete details on the use and execution of this protocol, please refer to Effern et al. (2020).
[Display omitted]
•Genome editing of tumor cells for experimental standardized T cell recognition•Tagging endogenous gene products with model CD8+ T cell epitopes in tumor cells•Assessing T cell responses directed against differentially regulated gene products•Approach allows studying the impact of the target antigen choice on T cell therapy
This protocol details the procedure for CRISPR-assisted insertion of epitopes (CRISPitope), a flexible approach for generating tumor cells expressing model CD8+ T cell epitopes fused to endogenously encoded gene products of choice. CRISPitope-engineered tumor cells can be recognized by T cell receptor-transgenic (TCRtg) CD8+ T cells that are widely used in immunology research. Using mice inoculated with CRISPitope-engineered tumor cells, researchers can investigate how the choice of the target antigen for T cell immunotherapies influences treatment efficacy and resistance mechanisms. |
|---|---|
| Bibliografie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Technical contact Lead contact |
| ISSN: | 2666-1667 2666-1667 |
| DOI: | 10.1016/j.xpro.2021.101038 |